Showing results (301-310 of 317) with videos related to

Sort By:
Pageof 32
JCI Insight|August 9, 2019
Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesiclesTanyalak Parimon, Changfu Yao, David M Habiel, et al.
Science (New York, N.Y.)|February 22, 2024
SOX9 switch links regeneration to fibrosis at the single-cell level in mammalian kidneysShikhar Aggarwal, Zhanxiang Wang, David Rincon Fernandez Pacheco, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 31, 2021
The allograft injury marker CXCL9 determines prognosis of anti-HLA antibodies after lung transplantationMichael Y Shino, Qiuheng Zhang, Ning Li, et al.
Thorax|March 13, 2016
Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosisSteven D Nathan, Carlo Albera, Williamson Z Bradford, et al.
JCI Insight|May 4, 2021
Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPFMiriam S Hohmann, David M Habiel, Milena S Espindola, et al.
Thorax|October 16, 2019
Risk factors for disease progression in idiopathic pulmonary fibrosisGanesh Raghu, Brett Ley, Kevin K Brown, et al.
Science Translational Medicine|September 27, 2019
Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosisBenjamin Ng, Jinrui Dong, Giuseppe D'Agostino, et al.
The New England Journal of Medicine|May 20, 2014
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosisLuca Richeldi, Roland M du Bois, Ganesh Raghu, et al.
The Lancet. Respiratory Medicine|December 13, 2016
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trialGanesh Raghu, Kevin K Brown, Harold R Collard, et al.
The Journal of Clinical Investigation|February 13, 2025
Metastatic tumor growth in steatotic liver is promoted by HAS2-mediated fibrotic tumor microenvironmentYoon Mee Yang, Jieun Kim, Zhijun Wang, et al.
Pageof 32